Glucagon like Peptide 1 News and Research

RSS

Scientists rethink GLP-1 delivery to improve dosing, tolerability, and adherence

The review highlights nanocarriers, microspheres, hydrogels, microneedles, long-acting formulations, and co-formulations as promising but mostly early-stage strategies that still require stronger long-term clinical evidence.

27 May 2026

Why blood pressure rises faster in women after midlife

This review examines how sex-specific blood pressure trajectories are shaped by genetics, hormones, metabolic risk factors, lifestyle exposures, environmental stressors, and medical treatments. It highlights that women generally have lower blood pressure earlier in life but may experience steeper increases with aging, especially around and after menopause, with exogenous stressors appearing to have a greater impact in women than in men.

27 May 2026

Retatrutide reshapes metabolism in obesity and type 2 diabetes, study finds

Retatrutide altered circulating metabolites and lipids linked to fatty acid oxidation and insulin resistance in people with obesity, with or without type 2 diabetes. These biomarker changes suggest improved metabolic health, but the post-hoc analysis remains hypothesis-generating and does not prove direct clinical benefit.

26 May 2026

Indian adapted Mediterranean diet targets inflammation in heart disease trial

The paper describes a single-center randomized controlled trial testing whether an Indian Adapted Mediterranean Diet can reduce dietary inflammation in adults with stable coronary artery disease or moderate-to-high cardiovascular risk. The protocol will assess changes in the Dietary Inflammatory Index, inflammatory biomarkers, cardiometabolic risk factors, body measurements, and metabolic hormones over six months.

25 May 2026

Oral AD109 improves sleep apnea severity but tolerability remains a challenge

AD109, an investigational once-daily oral combination of aroxybutynin and atomoxetine, significantly improved airway obstruction and oxygenation in adults with mild-to-severe obstructive sleep apnea who could not use PAP therapy. However, symptom improvements did not clearly differ from placebo, and about one in five AD109 recipients discontinued treatment due to adverse events.

21 May 2026

Methylene blue enhances hair follicle stem cell regeneration under stress

A new research paper was published in Volume 18 of Aging-US on May 5, 2026, titled "Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration."

19 May 2026

Endoscopic sleeve gastroplasty outperforms oral semaglutide in short-term weight loss

A comparative study, presented at ESGE Days 2026, has found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity.

15 May 2026

GLP-1 weight loss medications linked to significant drop in asthma flares

New research presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26 % fall in the number of asthma exacerbations and a 14% drop in use of asthma inhaler reliever use. The study is by Simon Høj and Dr Kjell Erik Julius Håkansson, Copenhagen University Hospital, Copenhagen, Denmark and colleagues.

15 May 2026

New obesity medications offer a potent tool for combating hypertension

A meta-analysis of 32 studies and 43,618 adults presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows that use of new classes of obesity drugs for weight loss is associated with a clinically relevant drop in blood pressure (BP): a 0.34 mmHg reduction in systolic BP per 1\% weight loss.

15 May 2026

Semaglutide significantly reduces obesity in treatment-resistant young adults

A weekly dose of semaglutide (2.4 mg) leads to a clinically significant reduction in body mass index (BMI) and related health outcomes in young adults with severe obesity who are treatment resistant following hospital-based non-pharmacological obesity care during childhood, according to a randomized controlled trial being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

13 May 2026

GLP-1 obesity drugs mainly reduce fat while preserving muscle mass

New research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that following treatment with GLP-1 drugs for obesity, most weight loss is fat mass (80–85%) and relative muscle mass is preserved.

13 May 2026

Two leading heart risk tools pass a major global test

A multinational Nature Medicine validation study found that PREVENT and SCORE2 cardiovascular risk equations performed generally well across 6.4 million people from observational cohorts and randomized trials. The findings support broader use of these tools for CVD risk stratification, while highlighting the need for local calibration and more validation in underrepresented regions.

11 May 2026

Semaglutide shows sustained weight loss benefits in older adults

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .

11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Greater weight loss from GLP-1 drugs lowers health complication risk

New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that, following treatment for obesity or diabetes or both using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to relatively lower risk of obesity-related conditions.

10 May 2026

People judge GLP-1 users more harshly than dieters

Stigma surrounding GLP-1 weight loss treatments reveals societal biases, impacting individuals' mental health and the effectiveness of obesity interventions.

7 May 2026

Bariatric surgery outperforms GLP-1 medications for obesity disease remission

Metabolic and bariatric surgery delivers significantly greater weight loss and higher rates of obesity-related disease remission than glucagon-like peptide-1 receptor agonists (GLP-1s), according to one of the largest and most comprehensive real-world comparisons of the two treatments.

6 May 2026

Popular GLP-1 drugs significantly reduce major cardiovascular events,

Researchers evaluate the long-term cardiovascular safety and efficacy of GLP-1RAs in high-risk populations.

6 May 2026

GLP-1 drugs combined with surgery yield superior weight loss results

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to new research presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

A new tool that predicts obesity-related disease risk beyond BMI

OBSCORE is a data-driven tool that identifies high-risk individuals for obesity-related diseases, enhancing treatment targeting beyond traditional BMI metrics.

5 May 2026